HGF
This randomised phase II study aims to assess the efficacy and safety of fluorouracil (FU), folinic acid (FA) and oxaliplatin-based chemotherapy (modified FOLFOX6 regimen) alone or combined to either panitumumab, an anti-EGFR monoclonal antibody, or to AMG 102, an anti-HGF monoclonal antibody, as first-line treatment for pts with AGEC.